{"nctId":"NCT00764946","briefTitle":"A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)","startDateStruct":{"date":"2008-10"},"conditions":["Human Immunodeficiency Virus"],"count":209,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: raltegravir"]}],"interventions":[{"name":"Comparator: raltegravir","otherNames":["ISENTRESS"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient is HIV positive\n* Patient agrees to use (or have their partner use) birth control as defined by the study doctor\n\nExclusion Criteria:\n\n* If female, pregnant or breastfeeding\n* Patient has used an investigational agent in the last 30 days\n* Patient has acute hepatitis\n* Patient has received MK0518 (raltegravir) before\n* Patient has used another experimental HIV-integrase inhibitor","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Achieved HIV Ribonucleic Acid (RNA) <50 Copies/mL at Week 48","description":"Numbers of participants with HIV RNA copies \\<50 copies/mL were summarized by race for each time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"43","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved HIV RNA <400 Copies/mL at Week 48","description":"Numbers of participants with HIV RNA copies \\<400 copies/mL were summarized by race for each time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 48 in HIV RNA","description":"Mean changes from baseline in plasma HIV RNA were summarized by race at each time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.62","spread":null},{"groupId":"OG001","value":"-1.16","spread":null},{"groupId":"OG002","value":"-2.49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.52","spread":null},{"groupId":"OG001","value":"-2.21","spread":null},{"groupId":"OG002","value":"-1.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline to Week 48 in CD4 Cell Count","description":"Mean changes from baseline in CD4 cell counts were summarized by race at each time point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141.0","spread":null},{"groupId":"OG001","value":"62.3","spread":null},{"groupId":"OG002","value":"208.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113.1","spread":null},{"groupId":"OG001","value":"69.2","spread":null},{"groupId":"OG002","value":"164.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Without Loss of Virologic Response","description":"For participants with confirmed HIV RNA levels \\<50 copies/mL on 2 consecutive visits, loss of virologic response is the occurrence of the first value \\>50 copies/mL or loss to follow-up; participants who never achieved HIV RNA \\<50 copies/mL on 2 consecutive visits are also considered as having loss of virologic response. Events are the numbers of participants with loss of virologic response versus the numbers of participants with no loss of virologic response (event free).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With One or More Adverse Events","description":"Numbers of participants with one or more adverse events were summarized by race.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"40","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Discontinued Due to an Adverse Event","description":"Numbers of participants who discontinued due to an adverse event were summarized by race.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":97},"commonTop":["Nausea","Upper respiratory tract infection","Diarrhoea","Vomiting","Oral candidiasis"]}}}